All Stories

  1. 2024 Update on Postmarketing Nutrivigilance Safety Profile: A Line of Dietary Food Supplements Containing Red Yeast Rice for Dyslipidemia.
  2. Patient experiences of their current asthma care and their views toward providing support for patients with asthma in community pharmacy: A Qualitative study
  3. Could siRNA therapeutics change the way we treat dyslipidemia?
  4. Using read-across to build physiologically-based kinetic models: Part 1. Development of a KNIME workflow to assist analogue selection for PBK modelling
  5. Using Read-Across to build Physiologically-Based Kinetic models: Part 2. Case studies for atenolol and flumioxazin
  6. Evaluation of Urolithin A Efficacy in Heart Failure Patients with Reduced Ejection Fraction: A Randomized, Double-blind, Crossover, Placebo-controlled Clinical Trial
  7. Adherence to the Atrial fibrillation Better Care pathway and the risk of adverse health outcomes in older care home residents with atrial fibrillation: a retrospective data linkage study 2003–18
  8. Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF) using sensors embedded in the handles of supermarket trolleys: A feasibility study.
  9. Pharmacist-led intervention for older people with atrial fibrillation in long-term care (PIVOTALL study): a randomised pilot and feasibility study
  10. Managing older people with atrial fibrillation and preventing stroke: a review of anticoagulation approaches
  11. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants
  12. S12 | Finding synergies for 3Rs – toxicokinetics, physiologically-based kinetic (PBK) models and read-across
  13. The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis
  14. Therapeutic drug monitoring: applying the ‘Goldilocks Principle’ to clinical pharmacology
  15. The role of nutraceuticals in heart failure muscle wasting as a result of inflammatory activity. The International Lipid Expert Panel (ILEP) Position Paper.
  16. Metabolic syndrome is associated with similar long-term prognosis in non-obese and obese patients. An analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 cohort studies
  17. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
  18. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
  19. Which Statin is Best for the Kidneys?
  20. Statin Intolerance: An Overview for Clinicians
  21. Do antihypertensive medicines increase the risk of depression?
  22. 1208 FEASIBILITY OF A PHARMACIST-LED INTERVENTION FOR ATRIAL FIBRILLATION IN LONG-TERM CARE: THE PIVOTALL STUDY
  23. Abstracts of the 18th Congress of the European Geriatric Medicine Society
  24. Prevalence and outcomes of atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018
  25. Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
  26. Anticoagulation in older people with atrial fibrillation moving to care homes: a data linkage study
  27. 2022: The Year in Cardiovascular Disease – The Year of Upfront Lipid Lowering Combination Therapy.
  28. Adherence to statin therapy - it seems we know everything, yet we do nothing…
  29. Individualized therapy in statin intolerance: the key to success
  30. Factors associated with prescription of oral anticoagulation for atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018
  31. Prevalence and outcomes of atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018
  32. Selected Abstracts from Pharmacology 2022
  33. Risk factors for post sternotomy wound complications across the patient journey: A systematised review of the literature
  34. Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel
  35. P17-04 An automated tool for selection of chemical analogues to facilitate development of new physiologically-based kinetic models using a read-across approach
  36. Integrated care for atrial fibrillation management: The role of the pharmacist
  37. 1300 Transfer of outpatient paediatric prescriptions to primary care via the Electronic Prescription Service (EPS)- community pharmacist views
  38. Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review
  39. Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?
  40. Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF): A Mixed Methods Feasibility Study Protocol
  41. Lifetime serum concentration of 25-hydroxyvitamin D 25(OH) is associated with hand grip strengths: insight from a Mendelian randomisation
  42. Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
  43. Prevalence of statin intolerance: a meta-analysis
  44. Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition
  45. Warfarin—Is Self-Care the Best Care?
  46. Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress
  47. Stop and Go: Barriers and Facilitators to Care Home Research
  48. Long-COVID-19: Definition, Epidemiology, and Clinical Implications
  49. CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities
  50. Potential Benefits of Phytochemicals for Abdominal Aortic Aneurysm
  51. The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study
  52. A Systematic Review of Published Physiologically based Kinetic Models and an Assessment of their Chemical Space Coverage
  53. Extreme cardiovascular risk—do we need a new risk category?
  54. Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study
  55. The management of asthma in adult patients in the community pharmacy setting: Literature review
  56. Associations between serum triglycerides and abdominal aortic calcification in a cross-sectional study from the United States of America
  57. Association between ankle-brachial index and cardiovascular mortality in a cohort from the United States of America
  58. The prevalence of statin intolerance worldwide: a systematic review and meta-analysis with 4,143,517 patients
  59. Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study
  60. Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland
  61. Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective
  62. Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta‐analysis of randomized controlled trials
  63. RNA Silencing in the Management of Dyslipidemias
  64. Bacterial lipopolysaccharide–Stoking the fire of residual risk?
  65. Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry
  66. The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis
  67. Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice
  68. Statins as anti-pyroptotic agents
  69. Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia
  70. Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors - analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies.
  71. Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations
  72. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP)
  73. Assessment of asthma management in adult patients: A retrospective case-note review in a general practice
  74. Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies
  75. Exploring pharmacists’ views surrounding conscientious objection to abortion and implications in practice
  76. Prevalence of anti-nuclear autoantibodies (ANA) in the general Polish population - analysis of the influence of sex and age on the variability of ANA.
  77. Effects of statins on myocarditis: A review of underlying molecular mechanisms
  78. OPTIMAL USE OF LIPID-LOWERING THERAPY AFTER ACUTE CORONARY SYNDROMES: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
  79. Drucebo effect – the challenge we should all definitely face!
  80. Lipid-lowering therapies: Better together
  81. OUP accepted manuscript
  82. Recent advancements in liposome-based strategies for effective drug delivery to the brain
  83. Management of Statin Intolerance
  84. Statins, COVID-19, and coronary artery disease: killing two birds with one stone
  85. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors
  86. Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go
  87. Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes
  88. Comparison of LDL-C calculation by friedewald and martin/hopkins methods in 12,243 adults from the United States of America
  89. LDL-C: lower is better for longer—even at low risk
  90. Pharmacist implementation of a treatment pathway for atrial fibrillation in care home residents
  91. The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
  92. Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic
  93. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
  94. Epigenetic control of atherosclerosis via DNA methylation: A new therapeutic target?
  95. Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice
  96. What's new in lipid‐lowering pharmacology? Integrating basic and clinical research to improve patient outcomes
  97. Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP)
  98. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
  99. The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP)
  100. Liposome Circulation Time is Prolonged by CD47 Coating
  101. Intake of Caffeine and Its Association with Physical and Mental Health Status among University Students in Bahrain
  102. Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants
  103. Application of PLGA nano/microparticle delivery systems for immunomodulation and prevention of allotransplant rejection
  104. Vitamin D and SAMS
  105. Inclisiran—New hope in the management of lipid disorders?
  106. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications
  107. Statins and Lp(a): do not make perfect the enemy of excellent
  108. The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis
  109. P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel
  110. Warfarin Therapy and Improved Anticoagulation Control by Patient Self-Management
  111. A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome
  112. Regulatory T cells: possible mediators for the anti-inflammatory action of statins
  113. Genetic testing in familial hypercholesterolaemia: What does it add?
  114. Poster Abstracts
  115. Worldwide Dyslipidemia Guidelines
  116. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials?
  117. Associations between the lipid profile and the development of hypertension in young individuals – the preliminary study
  118. Effects of carbohydrate-restricted diets on low-density lipoprotein cholesterol levels in overweight and obese adults: a systematic review and meta-analysis
  119. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions
  120. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
  121. Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
  122. Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study
  123. P3836The prognostic accuracy of bleeding risk prediction scores in patients with atrial fibrillation: a systematic review and meta-analysis
  124. P5086Associations between very low concentrations of LDL-Cholesterol, hsCRP and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
  125. Lipoprotein(a) and the risk of atrial fibrillation – is there a link
  126. The effects of cinnamon supplementation on blood lipid concentrations: A systematic review and meta-analysis
  127. The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis
  128. Autonomic and Autacoid Pharmacology: Goodbye and thank you
  129. Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review
  130. The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials
  131. 3100Effects of morning versus evening statin therapy on lipid profile: a systematic review and meta-analysis
  132. 3104Associations between cardiovascular disease, cancer and very low hdl cholesterol in the reasons for geographical and racial differences in stroke (REGARDS) study
  133. P627Associations between very low concentrations of LDL-cholesterol and health outcomes in the reasons for geographical and racial differences in stroke (REGARDS) Study
  134. Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis
  135. The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis
  136. 220 Daphnia magna as a model for quantifying chaos in cardiac arrhythmia
  137. Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease
  138. The role of nutraceuticals in the prevention of cardiovascular disease
  139. Evaluating bempedoic acid for the treatment of hyperlipidaemia
  140. Association between telomere length and complete blood count in US adults
  141. D-003 (Saccharum officinarum): The forgotten lipid-lowering agent
  142. Effects of pentoxifylline on inflammatory markers and blood pressure
  143. Sunday 28 August 2016
  144. Monday 29 August 2016
  145. Tuesday 30 August 2016
  146. Bioresorbable scaffold — A magic bullet for the treatment of coronary artery disease?
  147. Autonomic & Autacoid Pharmacology 2016: The year in review
  148. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – Some answers and still many questions
  149. Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials
  150. Autonomic & Autacoid Pharmacology: past, present and future
  151. Developing skills to deliver alcohol screening and brief intervention (SBI) in community pharmacy
  152. Lecturing: A lost art
  153. ChemInform Abstract: Synthesis of Antagonists of Muscarinic (M3) Receptors.
  154. Synthesis of antagonists of muscarinic (M3) receptors
  155. Incense – A problematic method of drug-delivery
  156. Activation of β-adrenoceptors mimics preconditioning of rat-isolated atria and ventricles against ischaemic contractile dysfunction
  157. Protective role of β2- and β3-adrenoceptors at reperfusion in isolated rat heart
  158. Vasopressors for cardiopulmonary resuscitation
  159. Effects of hypoxia on the vasodilator activity of nifedipine and evidence of secondary pharmacological properties
  160. The roles of alpha- and beta-adrenoceptor stimulation in myocardial ischaemia